Back to News
Sep 9, 2024 1:10 PM

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Monday, Immunovant, Inc. (NASDAQ:IMVT) reported results from the Phase 2a trial of batoclimab in Graves’ Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone.

Immunovant is a member of the Roivant Sciences Ltd. (NASDAQ:ROIV) family of companies.

Also Read: Vivek Ramaswamy-Founded Roivant’s Anti-Inflammatory Drug Aces Mid-Stage Study.

As previously disclosed, the batoclimab phase 2a trial in uncontrolled Graves’ Disease enrolled patients who were hyperthyroid despite antithyroid drugs (ATD) therapy.

Participants in the trial received 12 weeks of high-dose batoclimab, 680 mg weekly by subcutaneous injection (SC) followed by 12 weeks of lower-dose batoclimab, 340 mg ...